Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine
Lynn R. Webster(Adherent Technologies (United States)), A. L. Finn(BioDelivery Sciences International (United States)), Evan Tzanis(Paratek Pharmaceuticals (United States)), Qinfang Xiang(Endo Pharmaceuticals (United States)), Daniel Gruener, Todd Kirby(Endo Pharmaceuticals (United States))
Cited by 32
Related Papers
Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits
|Nature Genetics|2018|1.5k
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331
Sleep-Disordered Breathing and Chronic Opioid Therapy
|Pain Medicine|2007|309